Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CYP17A1 Double Nickase Plasmid (h): sc-401918-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP17A1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CYP17A1 Double Nickase Plasmid (h) and CYP17A1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CYP17A1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CYP17A1 Antibody (D-12): sc-374244
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP17A1 Double Nickase Plasmid (h) | sc-401918-NIC | 20 µg | $410.00 | |||
CYP17A1 Double Nickase Plasmid (h2) | sc-401918-NIC-2 | 20 µg | $410.00 |
CYP17A1 encodes cytochrome P450 17A1, a microsomal monooxygenase that catalyzes 17α-hydroxylase and 17,20-lyase reactions central to steroidogenesis. By converting pregnenolone and progesterone into 17-hydroxylated intermediates and subsequently generating dehydroepiandrosterone and androstenedione, CYP17A1 helps regulate flux through glucocorticoid and sex steroid biosynthetic pathways. Its activity integrates with electron transfer from P450 oxidoreductase in the endoplasmic reticulum and influences endocrine feedback circuits that control adrenal and gonadal hormone production. Dysregulated CYP17A1 function or expression is implicated in steroid hormone imbalance phenotypes and provides a mechanistic entry point for studying metabolism-linked signaling in endocrine-related disease models.
CYP17A1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CYP17A1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CYP17A1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CYP17A1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CYP17A1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.